ORIGINAL ARTICLES

Experience with direct molecular diagnosis of fragile X

J C Mulley, S Yu, A K Gedeon, A Donnelly, G Turner, D Loesch, C J Chapman, R J M Gardner, R I Richards, G R Sutherland

Abstract

The utility of the *pfxa3* probe for direct molecular diagnosis of the fragile X (*FRAXA*) has been established. This probe detects amplification of an unstable DNA element consisting of variable length CCG repeats. The size of the amplified fragment is correlated with phenotype and was determined using *PstI* digested DNA in family members. In 35 families with the fragile X, there was correspondence in 183 cases between the presence of an amplified unstable element and the presence of the fragile X chromosome independently determined by cytogenetics, position in the pedigree, or linked DNA markers flanking the fragile X. There was also correspondence in 124 cases between the presence of the normal 1.0 kb *PstI* fragment and absence of the fragile X chromosome independently determined by linked flanking markers. Six additional families considered to be isolated cases of 'fragile X' had been diagnosed before recognition of *FRAXD*. The *pfxa3* probe confirmed the cytogenetic diagnosis in three families, the other three being rediagnosed as non-fragile X. A further two families had consistent expression of a different folate sensitive fragile site, *FRAXE*, close to *FRAXA* but not associated with fragile X syndrome and not detectable with the *pfxa3* probe. Subsequent referrals were received from additional family members or from members of new families for whom carrier status had not been predetermined by linked markers. Direct *pfxa3* diagnosis for the 135 females within these 222 additional cases was confirmed by dosage analysis with the control probe *pS8*. Independent confirmation of the primary *pfxa3* diagnosis was helpful for correct diagnosis of females because of a small proportion who had an unstable element expressed as a faint smear of bands and because of the occasional presence of high molecular weight bands from incomplete *PstI* digestion. Diagnosis was definitive for all males using *pfxa3* alone in the presence of only one X chromosome.

Fragile X syndrome is the most common familial type of mental retardation in humans. The syndrome is associated with the folate sensitive fragile site at Xq27.3 (*FRAXA*). Families with fragile X syndrome had been previously ascertained on the basis of cytogenetic demonstration of the fragile site in a mentally impaired family member.

Genetic counselling for family members has been complicated by three factors. These are incomplete penetrance of cytogenetic expression of the fragile site in a proportion of female carriers, the occurrence of transmitting males who have the fragile X genotype but do not show mental impairment, and the presence of a common fragile site, *FRAXD*, at Xq27.2¹ which can be expressed at low frequency under the same conditions used to detect the fragile X. Transmitting males (defined as unaffected carrier males who have reproduced or have the potential to reproduce) have been detected either by risk analysis using closely linked polymorphic markers flanking the fragile X² or by their position in the pedigree. The occurrence of these asymptomatic male carriers is a unique phenomenon among X linked genetic disorders. However, the most puzzling phenomenon associated with fragile X has been the Sherman paradox,³⁴ suggesting a progressive increase in severity from generation to generation.

Molecular characterisation of the fragile X in three laboratories⁵⁻⁷ has made possible a direct test for the fragile X genotype in affected families. The existence of transmitting males, and the Sherman paradox, are now explicable in terms of the increase in size from generation to generation of the heritable unstable DNA element which is the molecular basis for this disorder.^{5,6,8,9} This unstable element consists of variable lengths of a repeating CCG trinucleotide sequence.^{8,10} The size of the *PstI* fragment containing this repeat is 1.0 kb in normal X chromosomes.⁸⁻¹⁰ What initiates amplification of the 1.0 kb fragment transforming it into a fragile X is not known; however, once the process has begun there is a direct correlation between the intellectual component of the fragile X phenotype, cytogenetic expression of the fragile site, and length of the unstable element which characterises the fragile X genotype.⁹ Whether the correlations between phenotype and length of the unstable element, and between cytogenetic

Department of Cytogenetics and Molecular Genetics, Adelaide Children's Hospital, North Adelaide, South Australia 5006, Australia.

J C Mulley
S Yu
A K Gedeon
A Donnelly
R I Richards
G R Sutherland

Tumbatin Developmental Clinic, Prince of Wales Children's Hospital, High Street, Randwick, NSW 2031, Australia.
G Turner

Department of Psychology, La Trobe University, Bundoora, Victoria 3083, Australia.
D Loesch

Department of Paediatrics, School of Medicine, University of Auckland, Auckland, New Zealand.
C J Chapman

Medical Genetics, Department of Paediatrics, Dunedin Hospital, Dunedin, New Zealand.
R J M Gardner

Correspondence to Dr Mulley.

Received 22 October 1991.
Revised version accepted 21 January 1992.

expression and length of the unstable element, represent continuous relationships, or step-wise relationships with discontinuity at a *Pst*I fragment size of approximately 1.6 kb, cannot be resolved without additional data.⁹ Females with larger amplifications (greater than 1.6 kb) were either normal or mentally affected, implying that additional factors such as non-random X inactivation may contribute to intellectual phenotype in females. The unstable element usually increases in size from one generation to the next when transmitted by females, but when transmitted by males remains the same size or decreases. The larger sized elements are somatically unstable and can present as multiple bands on Southern blots.^{5,6,8,9}

Materials and methods

PROBES

The pfxa3 probe is a 536 bp DNA fragment excised from pUC18 using the restriction endonuclease *Pst*I. The pfxa3 target sequence is located immediately distal to the unstable element which comprises the fragile X.⁵ The pfxa3 probe detects a 1.0 kb fragment on Southern blots of *Pst*I digested DNA from non-fragile X chromosomes, while the unstable fragile X element appears as a fragment of higher molecular weight. The pS8 probe is an 800 bp fragment excised from pUC19 using *Pst*I. This sequence was derived from a YAC containing the VK21 sequence and is used as an internal positive control probe in double hybridisation with the pfxa3 probe on *Pst*I

filters. It detects an 800 bp fragment on Southern blots. An autoradiograph showing the pfxa3 and pS8 fragments is shown in fig 1. The pfxa3 probe is available from Oncor, Inc, Box 870, Gaithersburg, MD 20884, USA.

HYBRIDISATION CONDITIONS

Hybridisation was carried out at 42°C in 5 × SSPE (pH 7.4), 1% SDS, 50% formamide, 10% dextran sulphate, and 100 µg/ml salmon sperm DNA. Filters were washed in 0.1% SDS and 0.1 × SSC (0.015 mol/l sodium chloride and 0.0015 mol/l sodium citrate) at 70°C for at least 30 minutes. The high stringency wash at 70°C is crucial for removal of lane background, presumably related to the high GC content of the probe, in order to visualise clearly the unstable element band or bands.

AC REPEAT MARKERS AT THE FRAGILE X

Two AC repeat markers detectable by the polymerase chain reaction (PCR) have been described: *FRAXAC1* and *FRAXAC2* within 10 kb of the fragile X¹¹ and *DXS548* 150 kb from the fragile X.⁷ Of the two within 10 kb of the fragile X, *FRAXAC2* is the more informative (heterozygosity 71%). *FRAXAC1* is in strong linkage disequilibrium with *FRAXAC2* and is therefore redundant for diagnosis. Primer sequences and reaction conditions were given by Richards *et al.*¹¹

RISK ANALYSIS

Carrier risks were computed for unaffected subjects in 35 fragile X families using linked DNA markers as previously described¹² but with closer markers.^{2,13} Risk analysis was applied to families where more than one subject had been clearly diagnosed by cytogenetic expression of the fragile X and this provided confirmation of pfxa3 diagnosis for unaffected subjects. Cytogenetic diagnosis had previously been carried out and thus provided confirmation of pfxa3 diagnosis for affected subjects. The map of linked markers used in the risk analysis was based on that previously established.^{2,13} This differs only very slightly from the map subsequently determined from the CEPH (Centre d'Etude du Polymorphisme Humain) families¹⁴ using the microsatellite markers *FRAXAC1* and *FRAXAC2* to represent the fragile site locus.¹¹

BASIS FOR DIAGNOSIS USING THE pfxa3 PROBE

*Pst*I digests are the most instructive since they give the necessary resolution on Southern analysis to distinguish male transmitters from normal males, to separate male transmitters from affected males, and to differentiate normal females from carrier females⁹ (fig 1). Diagnosis is unambiguous in males. Hybridisation with *Pst*I digested chromosomal DNA gives a 1.0 kb band in normal non-transmitting males, a band of up to 1.6 kb in male transmitters of the fragile X, and one or more bands of greater than 1.6 kb in males with fragile X syndrome.

Figure 1 Autoradiograph of *Pst*I digested DNA probed with pfxa3 and pS8. (1) Carrier female, (2) transmitting male, (3) non-carrier female, (4) affected male, (5) carrier female, (6) affected male, (7) non-carrier female, (8) normal non-transmitting male, (9) carrier female.

Where there is a smear of bands there may be bands within the 1.0 to 1.6 kb range in addition to bands in excess of 1.6 kb. Male transmitters and affected males do not have a band of normal intensity in the 1.0 kb position and usually have no band in the 1.0 kb position when the CCG repeat has been amplified.

*Pst*I digested DNA usually gives only a 1.0 kb band in the normal non-carrier females. Occasionally a doublet at 1.0 kb is detectable in non-carrier females who have two alleles at the extremes of the normal range of allele sizes for the CCG polymorphism. In all affected carrier females and some of the unaffected carrier females the *pfxa3* probe hybridises to a 1.0 kb fragment from the normal chromosome plus a fragment or fragments of greater than 1.6 kb from the fragile X chromosome. A faint smear of fragments greater than 1.6 kb in size may be difficult to detect. Unaffected carrier females all have either a 1.0 kb band and a band of up to 1.6 kb or the same pattern as the affected females; thus, the *pfxa3* probe cannot predict the intellectual phenotype of females when the *Pst*I fragment exceeds 1.6 kb. Carrier females with fragment size or sizes exceeding 1.6 kb usually express the fragile site cytogenetically, whereas females with a fragment size of 1.6 kb or less usually have only a single abnormal fragment which is clearly visible and they do not express the fragile site cytogenetically.⁹ Unlike males with a CCG amplification, females always have a clearly visible 1.0 kb fragment from the normal X chromosome.

Results and discussion

DETECTION OF FEMALE CARRIERS AND MALE TRANSMITTERS

An example of diagnosis using the *pfxa3* probe for one of the 35 families examined (which contained more than one carrier on the basis of cytogenetic analysis) is shown in fig 2. This pedigree shows those features routinely encountered in direct fragile X diagnosis using the *pfxa3* probe. The unstable element can be seen to increase in size from generation II (1.2 kb) to generation V (3.2 kb) with development of multiple bands (in IV.1, IV.19, and V.2) associated with the increase in size. The fragile X was detected using *pfxa3* for all affected boys for whom DNA was available (IV.1, IV.10, V.1). The obligate male transmitter (II.4) had a 1.2 kb fragment and the probable male transmitter (99.8% risk) (III.6) had a 1.3 kb fragment. The women shown to have the fragile X by cytogenetics were confirmed as carriers using the *pfxa3* probe (IV.2, IV.8, IV.19, V.2). The obligate female carriers for whom DNA was available, who did not express the fragile X (II.2, III.3, III.8, III.9, III.13, IV.5), were all shown to have abnormal *pfxa3* fragments. Two women (IV.17 and IV.18) ascertained as probable carriers (99%) using linked markers were shown as definite carriers using *pfxa3*. The remaining family members at low risk using linked markers (III.1, III.5, IV.3, IV.6, IV.9, IV.11, IV.13, IV.14, IV.15, IV.16, IV.20, IV.21) were confirmed as non-carriers using the *pfxa3* probe.

Figure 2 Fragile X pedigree showing typical behaviour of the unstable element detectable with *pfxa3*. The *pfxa3* genotype is shown for subjects from whom DNA was collected and consists of the normal 1.0 kb allele and the alleles of variable and abnormal size associated with the unstable element. Corresponding risks determined by linkage analysis are shown in parentheses and were based on pairwise flanking markers from within the set DXS292, DXS297, DXS304, and DXS52. (Marker genotypes are not shown.)

Figure 3 (A) Family with an isolated male with fragile X syndrome. (B) Family with an isolated affected female. Genotypes for *pfxa3* from *PstI* digested DNA are shown on the pedigrees.

sity to form multiple bands arising from somatic instability.

FAMILIES WITH ISOLATED CASES OF FRAGILE X SYNDROME

In addition to the familial cases described above, there were families with isolated cases which were confirmed as fragile X by detection of the unstable amplified fragment using *pfxa3*. Two of these families are shown in fig 3. Fig 3A shows a family with an isolated male (II.3) affected with fragile X syndrome. A smear of bands confirms the diagnosis for II.3. Observation of a 1.2 kb band for one of his brothers (II.4) was the only means of showing that this brother was a male transmitter. The observation of a 1.2 kb band for their mother (I.2) was also the only means of showing that she was a carrier and that II.3 was not a new mutation. A normal 1.0 kb band for II.2 confirms that his mental impairment is unrelated to the fragile X, in agreement with existing cytogenetic analysis which did not detect the fragile X, and the clinical observation of a non-fragile X phenotype. Neither II.1 nor II.2 carries the fragile X mutation.

An isolated female with fragile X syndrome is shown in fig 3B. Diagnosis of IV.6 as a definite carrier could not be made before analysis by *pfxa3*. Even with highly polymorphic AC repeat markers at the fragile X, such a diagnosis is unlikely to be made by linkage unless genotypes for I.1, I.2, II.1, II.2, II.4, and II.5 could all be inferred.

The possibility of new mutation as a cause for isolated cases of fragile X syndrome has been excluded for all cases examined so far.⁹ Recognition that 'isolated' cases of fragile X are all familial has had considerable impact on genetic counselling given to their relatives. Clarification of carrier status for relatives of such isolated cases has only been possible since the availability of direct molecular diagnosis.

EXCLUSION OF FRAGILE X SYNDROME

At the time when analysis of the initial 35 familial cases had been completed, six isolated cases had at least 2% of cells positive by cytogenetics and had been diagnosed as fragile X syndrome. Three of these six cases were

reclassified as non-fragile X syndrome on the basis of normal *pfxa3* fragments from *PstI* digested DNA. During the search for new mutations,⁹ further isolated cases which had been 'prediagnosed' by cytogenetics were selectively sought from collaborators in order to expand the number available for study. Of these, five isolated cases from a total of 11 were reclassified as non-fragile X syndrome on the basis of normal *pfxa3* fragments from *PstI* digested DNA. The proportion of such cases within collections from various laboratories will vary depending upon the quality of the cytogenetic analysis and on how recently this analysis was carried out. The existence of a common fragile site, *FRAXD*, at Xq27.2 is now well established¹ and is one explanation for misdiagnosis in cases completed before recognition of *FRAXD*. Isolated cases of fragile X should be retested using a probe which detects the unstable element. Thus, the *pfxa3* probe can be used to establish or exclude the diagnosis of fragile X syndrome for isolated cases in addition to determination of carrier status of males and females in families where the primary diagnosis has been established by unequivocal cytogenetics and confirmed by molecular analysis.

The problem of false positive cytogenetic diagnosis based on low rates of 'expression' is not restricted to isolated cases. They have been made within fragile X families and identified by linked flanking markers.¹⁵ Where false positive cytogenetic diagnoses could only be detected within families in the past by using linked markers, they are now easily ascertained using molecular diagnosis.

A NEW RARE FOLATE SENSITIVE FRAGILE SITE, *FRAXE*

At the time when analysis of the first 35 familial cases had established the reliability of the *pfxa3* probe for diagnosis, the *pfxa3* probe failed to detect an unstable element in the 'fragile X' family reported by Romain and Chapman.¹⁶ This family was unusual in that the 'fragile X' carriers did not have fragile X syndrome despite consistent expression of a folate sensitive fragile site at Xq27.3. The likely explanation is the presence in this family of a distinct fragile site, *FRAXE*, which has no

Figure 4 (A) A contaminating plasmid band of 6.5 kb is shown for a male in track 3. Track 5 shows incomplete digestion of DNA from a carrier female. (B) Tracks 8 and 9 show the pattern of incomplete digestion observed where digestion has proceeded almost to completion. (1) Carrier female, (2) carrier female, (3) normal male, (4) normal male, (5) carrier female, (6) normal male, (7) carrier female, (8) normal male, (9) carrier female. In (A) relative intensity of pfxa3 and pS8 bands is approximately equivalent and can be used for dosage analysis to confirm carrier status of females. In (B) the pS8 hybridisation is inadequate for reliable dosage analysis.

phenotypic effect but which maps in close proximity to *FRAXA*. The family of Romain and Chapman¹⁶ was described before the availability of pfxa3 analysis and has features similar to two other families that have been reported which have high fragile X expression without mental retardation.^{6,17} The families tested so far^{6,16} did not show the amplified pfxa3 fragment. In another recent ascertainment, *FRAXE* was shown to map distal to *FRAXA* by in situ hybridisation using probes near *FRAXA*.¹⁸ This confirms the existence of at least one other rare folate sensitive fragile site locus, *FRAXE*, located very close to *FRAXA*. The *FRAXE* site is not related to fragile X syndrome (associated with *FRAXA*) and is not the common fragile site (*FRAXD*) which is proximal to *FRAXA*.

ARTEFACTS

One pedigree showed a 6.5 kb fragment in three generations which mimicked mendelian inheritance. This fragment was unrelated to the pfxa3 detectable fragment, as indicated by dosage of the 1.0 kb pfxa3 allele, stability in 'transmission' from generation to generation, and presence of the 1.0 kb fragment in one man who also had the 6.5 kb fragment. It was confirmed as plasmid contamination by checking earlier autoradiographs used to analyse linked markers from the same DNA source and by reprobing the pfxa3 filter with plasmid sequence. Fig 4A shows the contaminating plasmid band and the pattern arising from what we interpret as incomplete digestion in a carrier female. Fig 4B shows clearer patterns of incomplete digestion. These artefacts need

to be distinguished from abnormal pfxa3 fragments in order to avoid false positive molecular diagnosis.

PRENATAL DIAGNOSIS

The first prenatal diagnosis using the pfxa3 probe has been described fully elsewhere.¹⁹ Fragile X genotype was detected in a male fetus and confirmed by cytogenetics and the informative flanking markers *DXS296* and *DXS297*. No evidence for somatic variation was found in fetal tissues suggesting that the size of the unstable element should be useful for predicting the phenotype prenatally as well as postnatally. Prediction of phenotype at prenatal diagnosis should be made with extreme caution when fragment sizes are close to 1.6 kb since this basis for separation of male transmitters from affected males has as yet been determined from only crude measurement of *PstI* fragment size on Southern blots.⁹ Prenatal diagnosis has also been reported using the probe Ox1.9.²⁰

If prenatal diagnosis is to be carried out more rapidly than is possible by Southern analysis, it needs to be based on PCR technology using highly polymorphic markers at or very close to the fragile X. When by Southern analysis the signal associated with abnormal pfxa3 fragments in some carrier females is weak (fig 1), extended exposure may be necessary to exclude the possibility of a false negative result. This is not a problem if the fetus is male where diagnosis can be carried out just as readily by observed absence of a normal 1.0 kb *PstI* fragment as by observation of abnormal size of the pfxa3 fragment, when the pS8 band is clearly present as a positive control (fig 1). PCR based diagnosis by linked AC repeat markers would provide rapid exclusion; however, a positive PCR diagnosis by linkage would need the additional pfxa3 result. Carrier males would be predicted to be mentally unaffected transmitters if the *PstI* fragment size was 1.6 kb or less and mentally affected if it exceeded 1.6 kb. Carrier females would be predicted to be mentally unaffected if the *PstI* fragment size was 1.6 kb or less. However, unlike males, there are at present insufficient data to enable phenotypic prediction for a female fetus who has a specific *PstI* fragment size which is greater than 1.6 kb. Having eliminated the possibility of mental impairment for carrier females with *PstI* fragment sizes of 1.6 kb or less, the remaining carrier females with *PstI* fragment sizes exceeding 1.6 kb must as a group be at greater risk of mental impairment than the risks given for the unsubdivided group.⁴ These risks were 32% when the fragile X was passed through an unimpaired mother and 55% when passed through an impaired mother.

Conclusions

The pfxa3 probe is a reliable diagnostic tool for detecting fragile X genotype and predicting fragile X phenotype when applied to *PstI* digested DNA. Used in conjunction with the pS8 probe, results may be checked for consistency by dosage analysis. Alternatively, used in

conjunction with closely linked and highly polymorphic AC repeat markers, results may be confirmed by family analysis without the need for laborious determination of RFLP markers by Southern analysis. There is no need for computerised risk analysis when using markers virtually in absolute linkage with *FRAXA*. These confirmatory procedures guard against the possibility of false positive molecular diagnosis caused by plasmid contamination or incomplete digestion. They also guard against false negative molecular diagnosis in those females who have not been cytogenetically tested and who have a low intensity smear of abnormal pfxa3 bands which could be easily masked by low level background. Such females are usually cytogenetically positive and therefore are unlikely to be misdiagnosed when parallel cytogenetic examination has been carried out. Carrier females who are cytogenetically negative are detectable without difficulty using the pfxa3 probe because they usually have only a single strongly hybridising fragment of 1.6 kb or less apart from the normal 1.0 kb fragment. Confirmatory family studies involving the AC repeat markers *FRAXAC2* or *DXS548* could be considered for inclusion in routine diagnostic protocols, not only to confirm the pfxa3 diagnosis and to carry out rapid PCR based prenatal diagnosis of genotype, but also to check for sample misidentification which can cause both false positive and false negative results.

The advent of molecular diagnosis raises the question of the role of cytogenetic analysis. Cytogenetic and molecular procedures will continue to be carried out in parallel until laboratories gain experience in molecular diagnosis. The initial ascertainment of fragile X families with amplification of the CCG repeat is likely to continue to be made by the cytogenetics laboratory from referrals for delayed development, or mental retardation, resulting from many causes. Molecular and cytogenetic diagnosis of fragile X syndrome might be complicated by a small number of cases which do not have an unstable element. These could result from mutation within the associated gene other than at the CCG repeat, such as a point mutation, microdeletion, or microduplication. One deletion has been detected and the extent of this deletion is being characterised in an affected boy where the pfxa3 probe failed to hybridise to *PstI* or *EcoRI* digested DNA (unpublished data).

PCR amplification of the polymorphic CCG repeat from normal chromosomes and those with small CCG amplifications now enables direct sizing of alleles at the fragile X locus.⁸ This analysis has established the allele distributions of this polymorphism in normal males and in male transmitters and confirmed an upper limit for amplification of 600 bp in transmitting males. Accurate delineation of these two groups by direct PCR genotyping would be preferable to separation based on estimation of *PstI* fragment size by Southern analysis. The PCR results, however, must be interpreted with caution given the extent of somatic instability in affected males, which may give rise to one or more additional bands in the

normal to transmitter range. This inherent difficulty precludes PCR analysis of CCG amplification from prenatal diagnosis. Conversely, direct PCR genotyping will exclude carrier state in females with two normal alleles as long as each corresponds to the unaffected allele of a parent or sib. Direct PCR genotyping has not been demonstrated for the large amplifications in excess of 600 bp. It is most likely that, together with PCR based genotyping of flanking AC repeats,¹¹ the PCR analysis of the fragile X CCG repeat will supplement, rather than replace, direct detection by Southern blots.

Note added in proof

Experience with direct molecular diagnosis of fragile X has also been reported using the probe StB12.3 by Rousseau *et al* (*N Engl J Med* 1991;325:1673-81).

This work was supported by grants from the National Health and Medical Research Council of Australia and the Adelaide Children's Hospital Research Trust.

- 1 Sutherland GR, Baker E. The common fragile site in band q27 of the human X chromosome is not coincident with the fragile X. *Clin Genet* 1990;37:167-72.
- 2 Suthers GK, Mulley JC, Voelckel MA, *et al*. Genetic mapping of new DNA probes at Xq27 defines a strategy for DNA studies in the fragile X syndrome. *Am J Hum Genet* 1991;48:460-7.
- 3 Sherman SL, Morton NE, Jacobs PA, Turner G. The marker (X) syndrome: a cytogenetic and genetic analysis. *Am J Hum Genet* 1984;48:21-37.
- 4 Sherman SL, Jacobs PA, Morton NE, *et al*. Further segregation analysis of the fragile X syndrome with special reference to transmitting males. *Hum Genet* 1985;69:289-99.
- 5 Yu S, Pritchard M, Kremer E, *et al*. Fragile X genotype characterised by an unstable region of DNA. *Science* 1991;252:1179-81.
- 6 Oberlé I, Rousseau F, Heitz D, *et al*. Instability of a 550-base pair DNA segment and abnormal methylation in fragile X syndrome. *Science* 1991;252:1097-102.
- 7 Verkerk AJMH, Pieretti M, Sutcliffe JS, *et al*. Identification of a gene (FMR-1) containing a CCG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. *Cell* 1991;65:905-14.
- 8 Fu Y-H, Kuhl DPA, Pizzuti A, *et al*. Variation of the CCG repeat at the fragile X site results in genetic instability: resolution of the Sherman paradox. *Cell* 1991;67:1047-58.
- 9 Yu S, Mulley J, Loesch D, *et al*. Fragile X syndrome: unique genetics of the heritable unstable element. *Am J Hum Genet* 1992;50.
- 10 Kremer EJ, Pritchard M, Lynch M, *et al*. Mapping of DNA instability at the fragile X to a trinucleotide repeat sequence p(CCG)_n. *Science* 1991;252:1711-14.
- 11 Richards RI, Holman K, Kozman H, *et al*. Fragile X syndrome: genetic localisation by linkage mapping of two microsatellite repeats *FRAXAC1* and *FRAXAC2* which immediately flank the fragile site. *J Med Genet* 1991;28:818-23.
- 12 Mulley JC, Gedeon AK, Thorn KA, Bates LJ, Sutherland GR. Linkage and genetic counselling for the fragile X using DNA probes 52A, F9, DX13 and St14. *Am J Med Genet* 1987;27:435-48.
- 13 Richards RI, Shen Y, Holman K, *et al*. Fragile X syndrome: diagnosis using highly polymorphic microsatellite markers. *Am J Hum Genet* 1991;48:1051-7.
- 14 Dausset J, Cann H, Cohen D, Lathrop GM, Lalouel JM, White R. Centre d'Étude du Polymorphisme Humain (CEPH): collaborative genetic mapping of the human genome. *Genomics* 1990;6:575-7.
- 15 Mulley JC, Turner G, Bain S, Sutherland GR. Linkage between the fragile X and F9, *DXS52* (St14), *DXS98* (4D-8) and *DXS105* (cX55.7). *Am J Med Genet* 1988;30:567-80.
- 16 Romain DR, Chapman CJ. Fragile site Xq27.3 in a family without mental retardation. *Clin Genet* (in press).
- 17 Voelckel MA, Philip N, Piquet C, *et al*. Study of a family with a fragile site of the X chromosome at Xq27-28 without mental retardation. *Hum Genet* 1989;81:353-7.
- 18 Sutherland GR, Baker E. Characterization of a new rare fragile site easily confused with the fragile X. *Hum Mol Genet* (in press).
- 19 Sutherland GR, Gedeon A, Kornman L, *et al*. Prenatal diagnosis of fragile X syndrome by direct detection of the characteristic unstable DNA element. *N Engl J Med* 1991;325:1720-2.
- 20 Hirst M, Knight S, Davies K, *et al*. Prenatal diagnosis of fragile X syndrome. *Lancet* 1991;338:956-7.